While highly effective treatments exist for aortic stenosis (AS), innovations in care have not been equally utilized by AS patients. Treatment disparities span a broad range of patient demographics, including race, ethnicity, gender, socioeconomic status (SES), and insurance status. Structural heart (SH) programs have an opportunity to proactively identify disparities and address unmet care needs for the patients they serve.
Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
This report is sponsored by Edwards Lifesciences, an Advisory Board member organization. Representatives of Edwards Lifesciences helped select the topics and issues addressed. Advisory Board experts wrote the report, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.
To learn more, view our editorial guidelines.
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
Never miss out on the latest innovative health care content tailored to you.